tamoxifen Cancer Research Results

Tam, tamoxifen: Click to Expand ⟱
Features:
Tamoxifen is an endocrine anti-hormone drug used to treat breast cancer and other tumours. Tamoxifen is a hormone therapy that treats or prevents hormone receptor-positive breast cancer.

Tamoxifen (TAM; brands include Nolvadex, Soltamox) — an oral selective estrogen receptor modulator (SERM) used primarily for ER+ breast cancer treatment and risk-reduction. Acts as an estrogen receptor antagonist in breast tissue, with partial agonist effects in other tissues.

Primary mechanisms (conceptual rank):
1) ER antagonism in breast → ↓ estrogen-driven transcription/proliferation
2) Prodrug activation to endoxifen (CYP2D6-dependent) → clinical response modulation
3) Cell-cycle arrest + apoptosis downstream of ER blockade (context-dependent)
4) Tumor microenvironment / growth factor cross-talk modulation (e.g., IGF signaling; context-dependent)

Bioavailability / PK relevance: Long half-life; highly protein-bound; hepatic metabolism. Conversion to active metabolite endoxifen depends in part on CYP2D6 activity and interacting drugs. :contentReference[oaicite:0]{index=0}

In-vitro vs oral exposure: Many non-ER “off-target” cytotoxic mechanisms (e.g., lysosomal/mitochondrial disruption) are reported at higher concentrations than typical clinical free-drug exposure; clinically dominant mechanism is ER modulation in ER+ disease. :contentReference[oaicite:1]{index=1}

Clinical evidence status: Established standard therapy and prevention option for ER+ breast cancer; labeling includes serious risks (uterine malignancies and thromboembolic events).

Tamoxifen — Cancer vs Normal Cell Pathway Map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Estrogen Receptor (ERα) transcriptional program ↓ (primary; ER+) ↔ / ↑ (tissue-dependent partial agonism) R/G Antiestrogen growth blockade Core mechanism in ER+ breast cancer; antagonist in breast, partial agonist in endometrium/bone context. :contentReference[oaicite:3]{index=3}
2 Endoxifen activation (CYP2D6-dependent) ↑ efficacy with adequate activation ↔ G Active metabolite exposure Tamoxifen is a prodrug; CYP2D6 affects endoxifen levels and may affect outcomes (drug interactions can matter). :contentReference[oaicite:4]{index=4}
3 Cell cycle (G1 checkpoint; cyclin/CDK) ↓ proliferation (ER+) ↔ G Cytostatic growth arrest Downstream of ER blockade; strongest in hormone-dependent contexts. :contentReference[oaicite:5]{index=5}
4 Apoptosis ↑ (context-dependent) ↔ G Tumor cell death in responsive settings Typically secondary to sustained estrogen deprivation/ER antagonism; variable by tumor biology. :contentReference[oaicite:6]{index=6}
5 PI3K/AKT/mTOR cross-talk ↔ / ↓ (context-dependent) ↔ R/G Growth-factor pathway interplay Common resistance axis in endocrine therapy; not tamoxifen’s primary biochemical target. :contentReference[oaicite:7]{index=7}
6 ROS ↔ / ↑ (high concentration only) ↔ P/R Not a dominant on-target axis Oxidative/mitochondrial effects are reported mainly in vitro at higher concentrations than typical free systemic exposure.
7 NRF2 ↔ ↔ R/G No primary modulation Not a canonical tamoxifen mechanism.
8 HIF-1α ↔ ↔ G No primary role Any hypoxia-axis effects are indirect and model-dependent.
9 Ferroptosis ↔ (not established) ↔ R/G Not canonical Not an established primary mechanism for tamoxifen.
10 Ca²⁺ signaling ↔ ↔ P/R No primary role Not a dominant on-target axis.
11 Clinical Translation Constraint ↓ (constraint) ↓ (toxicity) — Risk + interactions + resistance Key constraints include uterine malignancy and thromboembolic risks (esp. prevention setting), CYP2D6-dependent activation/interaction issues, and endocrine resistance. :contentReference[oaicite:8]{index=8}

TSF legend: P: 0–30 min (receptor binding); R: 30 min–3 hr (acute transcriptional signaling shifts); G: >3 hr (cell-cycle/apoptosis phenotypes)
Scientific Papers found: Click to Expand⟱
386- AgNPs,  Tam,    Synergistic anticancer effects and reduced genotoxicity of silver nanoparticles and tamoxifen in breast cancer cells
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
P53↑, BAX↑, Bcl-2↓, Casp3↑, DNAdam↑, TumCCA↑,
996- Ba,  Tam,    Baicalein resensitizes tamoxifen‐resistant breast cancer cells by reducing aerobic glycolysis and reversing mitochondrial dysfunction via inhibition of hypoxia‐inducible factor‐1α
- in-vitro, BC, NA
Hif1a↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, lact/pyru↓, ROS↑, Apoptosis↑,
8830- DIM,  Tam,    A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen
- Trial, BC, NA
Dose?, 2/16-OHE1↓, SHBG↑,
6276- DL,  Tam,    Combination of tamoxifen and D-limonene enhances therapeutic efficacy in breast cancer cells
- in-vitro, BC, MCF7
TumCG↓, tumCV↓, TumCCA↑, cycD1/CCND1↓, CycB/CCNB1↓, Apoptosis↑,
8588- FS,  Tam,    Dietary flaxseed and tamoxifen affect the inflammatory microenvironment in vivo in normal human breast tissue of postmenopausal women
- in-vivo, BC, NA
BioAv↑, Dose↝, IL-1Ra↑, IL1R2↑, IL18↑, IL1RL1/ST2↑, MMP9↑, eff↑,
8595- FS,  Tam,    Flaxseed cotyledon fraction reduces tumour growth and sensitises tamoxifen treatment of human breast cancer xenograft (MCF-7) in athymic mice
- in-vitro, BC, MCF7
TumCP↓, ChemoSen↑,
293- HCA,  Tam,    Hydroxycitric acid potentiates the cytotoxic effect of tamoxifen in MCF-7 breast cancer cells through inhibition of ATP citrate lyase
- in-vitro, BC, MCF7
TumCG↓, Apoptosis↑, ACLY↓, ACC-α↓, Fas↓, ChemoSen↑,
1629- HCA,  Tam,    Hydroxycitric acid reverses tamoxifen resistance through inhibition of ATP citrate lyase
- in-vitro, BC, MCF7
ACLY↓, eff↓, tumCV↓, eff↑, Casp3↑, BAX↑, Bcl-2↓, ChemoSen↑,
8777- MSM,  Tam,    The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenografts
- in-vitro, BC, MCF7 - in-vitro, BC, T47D
tumCV↓, TumCMig↓, JAK2↓, STAT5↓, ChemoSen↑, cycD1/CCND1↓, VEGF↓, IGF-1↓, IGF-1R↓, MMP2↓, MMP3↓, MMP9↓, TumVol↓, STAT3↓,
926- QC,  PacT,  doxoR,  Tam,    Bioenhancers from mother nature and their applicability in modern medicine
- Review, Nor, NA
*BioEnh↑, BioEnh↑, BioEnh↑, BioEnh↑, BioEnh↑, BioEnh↑, BioEnh↑, P-gp/ABCB1↓,
156- Ralox,  Tam,  GEN,  CUR,    Modulators of estrogen receptor inhibit proliferation and migration of prostate cancer cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
ERβ/ESR2↑, TumCG↓, TumCMig↓, FAK↓, p38↓,

Showing Research Papers: 1 to 11 of 11

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 11

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACC-α↓, 1,   ACLY↓, 2,   GlucoseCon↓, 1,   Glycolysis↓, 1,   lact/pyru↓, 1,   lactateProd↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 3,   BAX↑, 2,   Bcl-2↓, 2,   Casp3↑, 2,   Fas↓, 1,   p38↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

IGF-1R↓, 1,   JAK2↓, 1,   STAT3↓, 1,   STAT5↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 3,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   P53↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CycB/CCNB1↓, 1,   cycD1/CCND1↓, 2,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

IGF-1↓, 1,   TumCG↓, 3,   TumCP↓, 1,  

Migration(tgid=13) ⓘ

FAK↓, 1,   MMP2↓, 1,   MMP3↓, 1,   MMP9↓, 1,   MMP9↑, 1,   TumCMig↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

Hif1a↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL-1Ra↑, 1,   IL18↑, 1,   IL1R2↑, 1,   IL1RL1/ST2↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

2/16-OHE1↓, 1,   ERβ/ESR2↑, 1,   SHBG↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   BioEnh↑, 6,   ChemoSen↑, 4,   Dose?, 1,   Dose↝, 1,   eff↓, 1,   eff↑, 2,   P-gp/ABCB1↓, 1,  

Functional Outcomes(tgid=23) ⓘ

TumVol↓, 1,  
Total Targets: 50

Pathway results for Effect on Normal Cells:


Drug Metabolism & Resistance(tgid=21) ⓘ

BioEnh↑, 1,  
Total Targets: 1

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:189  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page